The top five affected signaling pathways were ERBB, PI3K-AKT, cell cycle, FGF, and homologous recombination deficiency in PR and metastatic tumors, with a higher frequency of mutations in patients with metastasis (Figure 4). The gene discussed is EGFR; the disease is metastatic neoplasm.